James Harwood, a biochemist and lipid enzymologist, brings over 35 years of research expertise in studying the physiological and pharmacologic modulation of key enzymes and receptors involved in the regulation of intermediary metabolism and over 25 years of broad based expertise in drug discovery and development in the pharmaceutical industry.Presently, Jim is founder and Chief Consultant of Delphi BioMedical Consultants LLC, a consulting practice servicing the pharmaceutical and biotechnology industries, Adjunct Professor in the Department of Cellular and Molecular Biology at the University of Rhode Island where he teaches Biochemistry and advises pre-health profession students, and Adjunct Professor in the Department of Pathology at the Wake Forest University School of Medicine where he collaborates to study metabolic diseases in non-human primates.Prior to this, Jim was Principal Research Investigator in the Department of Cardiovascular and Metabolic Diseases at Pfizer Global R & D where some of his key projects included discovery and development of cholesterol synthesis inhibitors, cholesterol absorption inhibitors, fatty acid synthesis inhibitors, fat absorption inhibitors, and fat metabolism enhancers.Prior to these activities, he was Assistant Professor in the Departments of Medicine and Pharmacology at the University of Florida where he studied the physiological and pharmacologic regulation of cholesterol metabolism in experimental animals and in humans.Jim earned his Ph.D. in Biochemistry in 1982 from Purdue University and has authored over seventy publications in scientific journals.